Skip to content
Artwork for Pharmaceutical Executive
ScienceLife Sciences

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 
Play
  • 84 episodes
  • Avg 6 min
  • English
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • July 16 · 27 min

    The Power of Better Questions: How Great Leaders Balance Risk, Growth and Curiosity

    What separates exceptional life sciences leaders from merely capable ones? According to veteran biopharma executive Craig Tooman, it often comes down to one deceptively simple skill: asking the right questions. In this episode of Leading Edge with Ken Banta, Tooman reflects on the lessons from a career journey spanning clinical, operational, financial and capital market roles, including as the CEO of Silence Therapeutics, and shares how curiosity, disciplined thinking and openness to unexpected opportunities have shaped his leadership philosophy. Joined by Ken Banta, The Vanguard Network founder and CEO, and Pharmaceutical Executive's Mike Christel, the discussion examines how leaders can balance prudent risk management with long-term growth, cultivate cultures where cross-functional teams challenge assumptions and avoid the groupthink that often stifles innovation. The conversation also explores the changing role of AI in decision-making, why human judgment remains indispensable and how today's CEOs must think differently about funding, scientific strategy and organizational adaptability in an increasingly complex industry.

  • July 15 · 3 min

    Pharmaceutical Executive Daily: FDA Approves Reytorpyk for Advanced Breast Cancer

    In today's Pharmaceutical Executive Daily, Steer Bio discusses its regenerative cell therapy platform for cancer-related lymphedema, FDA approves Celcuity's Revtorpyk as the first pan-PI3K and mTORC1/2 inhibitor for advanced breast cancer, and Insilico Medicine enters a strategic alliance with Bora Pharmaceuticals worth up to $2.5 billion.

  • July 14 · 2 min

    Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik

    In today's Pharmaceutical Executive Daily, AstraZeneca acquires global rights to Dizal Pharmaceutical's lung cancer drug Zegfrovy in a deal worth up to $1.5 billion, FDA approves a subcutaneous formulation of Leqembi for early Alzheimer's disease, and a pharmacy executive weighs in on the education gap facing patients starting GLP-1 therapies.

  • July 13 · 2 min

    Pharmaceutical Executive Daily: FDA Issues CRL to Elevar Therapeutics

    In today's Pharmaceutical Executive Daily, a new industry analysis warns that direct-to-patient pharma platforms are scaling faster than the safety infrastructure needed to support them, FDA issues a complete response letter to Elevar Therapeutics over manufacturing deficiencies in its liver cancer combination therapy, and Insilico Medicine deepens its partnership with China Medical System Holdings in a new AI-powered drug discovery collaboration worth up to $177 million.

Showing 81–84 of 84 episodes